2.36
price up icon31.11%   0.56
after-market アフターアワーズ: 2.37 0.01 +0.42%
loading
前日終値:
$1.80
開ける:
$2.05
24時間の取引高:
10.66M
Relative Volume:
6.06
時価総額:
$274.42M
収益:
$6.65M
当期純損益:
$-136.32M
株価収益率:
-2.0563
EPS:
-1.1477
ネットキャッシュフロー:
$-112.04M
1週間 パフォーマンス:
+81.54%
1か月 パフォーマンス:
+93.44%
6か月 パフォーマンス:
+116.51%
1年 パフォーマンス:
+101.71%
1日の値動き範囲:
Value
$1.975
$2.36
1週間の範囲:
Value
$1.22
$2.36
52週間の値動き範囲:
Value
$0.91
$2.36

Fate Therapeutics Inc Stock (FATE) Company Profile

Name
名前
Fate Therapeutics Inc
Name
セクター
Healthcare (1106)
Name
電話
858.875.1803
Name
住所
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
Name
職員
161
Name
Twitter
@fatethx
Name
次回の収益日
2026-05-12
Name
最新のSEC提出書
Name
FATE's Discussions on Twitter

Compare FATE vs VRTX, REGN, ARGX, ALNY, ONC

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
FATE icon
FATE
Fate Therapeutics Inc
2.36 209.31M 6.65M -136.32M -112.04M -1.1477
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
424.36 109.34B 12.32B 4.34B 3.19B 16.86
REGN icon
REGN
Regeneron Pharmaceuticals Inc
702.27 74.35B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
794.70 50.44B 4.16B 1.29B 734.26M 19.58
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
301.11 39.78B 3.71B 313.75M 465.38M 2.2571
ONC icon
ONC
Beone Medicines Ltd Adr
297.49 33.02B 5.36B 287.73M 924.18M 2.5229

Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-10-31 アップグレード H.C. Wainwright Neutral → Buy
2025-10-27 アップグレード Wedbush Neutral → Outperform
2024-11-18 アップグレード BofA Securities Underperform → Neutral
2024-06-17 アップグレード Piper Sandler Neutral → Overweight
2023-03-27 再開されました Wells Fargo Equal Weight
2023-01-24 ダウングレード H.C. Wainwright Buy → Neutral
2023-01-06 ダウングレード BMO Capital Markets Outperform → Market Perform
2023-01-06 ダウングレード BofA Securities Buy → Underperform
2023-01-06 ダウングレード Cowen Outperform → Market Perform
2023-01-06 ダウングレード Piper Sandler Overweight → Neutral
2023-01-06 ダウングレード Stifel Buy → Hold
2023-01-06 ダウングレード Truist Buy → Hold
2023-01-06 ダウングレード Wedbush Outperform → Neutral
2023-01-03 ダウングレード Guggenheim Buy → Neutral
2022-12-22 ダウングレード Oppenheimer Outperform → Perform
2022-12-15 開始されました Goldman Sell
2022-11-04 再開されました Cantor Fitzgerald Overweight
2022-10-10 開始されました Canaccord Genuity Buy
2022-08-18 再開されました Wells Fargo Overweight
2022-07-28 開始されました Needham Hold
2022-07-11 アップグレード BMO Capital Markets Market Perform → Outperform
2022-06-03 開始されました Robert W. Baird Neutral
2022-02-11 再開されました BMO Capital Markets Market Perform
2021-12-15 アップグレード Wedbush Neutral → Outperform
2021-12-07 開始されました Cowen Outperform
2021-11-09 アップグレード Citigroup Neutral → Buy
2021-08-26 開始されました Morgan Stanley Equal-Weight
2021-06-07 アップグレード H.C. Wainwright Neutral → Buy
2021-05-07 アップグレード Wedbush Neutral → Outperform
2021-04-26 再開されました Jefferies Buy
2021-02-26 開始されました BofA Securities Buy
2021-02-26 ダウングレード Wedbush Outperform → Neutral
2021-02-11 ダウングレード Citigroup Buy → Neutral
2021-01-27 再開されました H.C. Wainwright Neutral
2020-05-13 開始されました H.C. Wainwright Buy
2020-03-04 開始されました Barclays Overweight
2020-01-09 ダウングレード BMO Capital Markets Outperform → Market Perform
2019-12-30 繰り返されました Mizuho Buy
2019-12-09 アップグレード Wells Fargo Market Perform → Outperform
2019-11-12 開始されました SunTrust Buy
2019-11-06 ダウングレード Wells Fargo Outperform → Market Perform
2019-10-01 開始されました Stifel Buy
2019-08-09 開始されました BTIG Research Buy
2019-07-22 開始されました Cantor Fitzgerald Overweight
2019-07-12 開始されました Oppenheimer Outperform
2019-06-13 開始されました Mizuho Buy
2019-06-07 開始されました ROTH Capital Neutral
2019-05-31 開始されました Guggenheim Buy
2019-05-24 再開されました Citigroup Buy
2019-03-28 開始されました SVB Leerink Outperform
2019-01-03 ダウングレード Stephens Overweight → Equal-Weight
2018-11-05 開始されました Jefferies Buy
2018-08-01 開始されました Citigroup Buy
2018-03-06 ダウングレード H.C. Wainwright Buy → Neutral
すべてを表示

Fate Therapeutics Inc (FATE) 最新ニュース

pulisher
May 05, 2026

Fate Therapeutics (FATE) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat

May 05, 2026
pulisher
May 05, 2026

FDA selects Fate Therapeutics’ FT819 for manufacturing pilot program - Investing.com

May 05, 2026
pulisher
May 05, 2026

Fate Therapeutics selected for U.S. FDA chemistry, manufacturing, and controls development and readiness pilot program to support manufacturing readiness of FT819 - marketscreener.com

May 05, 2026
pulisher
May 05, 2026

FDA selects Fate Therapeutics’ FT819 for manufacturing pilot program By Investing.com - Investing.com Canada

May 05, 2026
pulisher
May 05, 2026

FDA picks Fate's lupus cell therapy for manufacturing-readiness pilot - Stock Titan

May 05, 2026
pulisher
May 05, 2026

Fate Therapeutics Selected For U.S. FDA Chemistry, Manufacturing, And Controls Development And Readiness Pilot Program To Support Manufacturing Readiness Of Ft819 - TradingView

May 05, 2026
pulisher
May 05, 2026

Fate Therapeutics Selected for U.S. FDA Chemistry, - GlobeNewswire

May 05, 2026
pulisher
May 04, 2026

Off-the-shelf CAR-T studies target lupus, diabetes and cancer - Stock Titan

May 04, 2026
pulisher
May 04, 2026

Fate Therapeutics announces three presentations at the 2026 ASGCT annual meeting highlighting off-the-shelf CAR T-cell therapy pipeline for cancer and autoimmune diseases - marketscreener.com

May 04, 2026
pulisher
May 04, 2026

Fate Therapeutics Announces Three Presentations at the 2026 ASGCT Annual Meeting Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases - Yahoo Finance UK

May 04, 2026
pulisher
May 04, 2026

H.C. Wainwright raises Fate Therapeutics price target to $7 on SLE data - Investing.com Canada

May 04, 2026
pulisher
May 04, 2026

H.C. Wainwright Maintains Fate Therapeutics(FATE.US) With Buy Rating, Raises Target Price to $7 - Moomoo

May 04, 2026
pulisher
May 03, 2026

FATE Stock Rises As Fate Therapeutics Showcases FT839 CAR T Data​ - StocksToTrade

May 03, 2026
pulisher
May 03, 2026

MSN Money - MSN

May 03, 2026
pulisher
May 01, 2026

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

May 01, 2026
pulisher
May 01, 2026

New Fate hire gets 30,200 shares in Nasdaq-compliant award - Stock Titan

May 01, 2026
pulisher
May 01, 2026

FATE Stock Price, Quote & Chart | FATE THERAPEUTICS INC (NASDAQ:FATE) - ChartMill

May 01, 2026
pulisher
Apr 30, 2026

CAR-T Cell Therapy Market Will Generate Booming Growth Opportunities to 2030 | Novartis, Johnson & Johnson Services, Mustang, Sorrento Therapeutics, Fate Therapeutics etc. - industrytoday.co.uk

Apr 30, 2026
pulisher
Apr 30, 2026

Single-dose FT819 data in 10 lupus patients heads to rheumatology meeting - Stock Titan

Apr 30, 2026
pulisher
Apr 30, 2026

Fate Therapeutics Announces Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Lupus Erythematosus (SLE) at the CCR – East 2026 Meeting - ChartMill

Apr 30, 2026
pulisher
Apr 24, 2026

Fate Therapeutics (NASDAQ: FATE) sets 2026 proxy votes and 7M-share plan boost - Stock Titan

Apr 24, 2026
pulisher
Apr 24, 2026

Fate Therapeutics | DEF 14A: Definitive information statements - Moomoo

Apr 24, 2026
pulisher
Apr 23, 2026

iPSC-Derived NK Cells Pipeline Set to Transform Cancer Immunotherapy Landscape with 15+ Emerging Therapies and Strong Innovation Momentum from Century Therapeutics, Fate Therapeutics | DelveInsight - Barchart

Apr 23, 2026
pulisher
Apr 23, 2026

Redmile (NASDAQ: FATE) corrects cash-settled swap reference price - Stock Titan

Apr 23, 2026
pulisher
Apr 23, 2026

iPSC-Derived NK Cells Pipeline Set to Transform Cancer - openPR.com

Apr 23, 2026
pulisher
Apr 22, 2026

Redmile (NASDAQ: FATE) shifts stake to SPV in internal reorg - Stock Titan

Apr 22, 2026
pulisher
Apr 21, 2026

FATE Financials: Income Statement, Balance Sheet & Cash Flow | Fate Therapeutic - Stock Titan

Apr 21, 2026
pulisher
Apr 20, 2026

Fate Therapeutics (FATE) Stock: Why Market Expansion (Breakdown Watch) 2026-04-20Social Buzz - UBND thành phố Hải Phòng

Apr 20, 2026
pulisher
Apr 17, 2026

Fate Therapeutics Announces Data Presentation of FT839 Next-Generation Off-The-Shelf CAR T-Cell Product Candidate for the Broad Treatment of Hematological Malignancies and Autoimmune Diseases - marketscreener.com

Apr 17, 2026
pulisher
Apr 17, 2026

Fate Therapeutics Announces Data Presentation of FT839 Next-Generation Off-The-Shelf CAR T-Cell Product Candidate for the Broad Treatment of Hematological Malignancies and Autoimmune Diseases Without the Need for Conditioning Chemotherapy at t - Sahm

Apr 17, 2026
pulisher
Apr 17, 2026

Fate Therapeutics, Inc. (NASDAQ:FATE) Given Average Recommendation of "Hold" by Brokerages - MarketBeat

Apr 17, 2026
pulisher
Apr 16, 2026

Fate Therapeutics Announces Data Presentation Of FT839 Next-Generation Off-The-Shelf CAR T-Cell Product Candidate For The Broad Treatment Of Hematological Malignancies And Autoimmune Diseases Without The Need For Conditioning Chemotherapy - marketscreener.com

Apr 16, 2026
pulisher
Apr 16, 2026

Fate Therapeutics Details Off-the-Shelf CAR T Progress in Lupus and Solid Tumors at Needham Conference - MarketBeat

Apr 16, 2026
pulisher
Apr 14, 2026

NK Cell Therapy Market Is Booming Rapidly with Strong Demand - openPR.com

Apr 14, 2026
pulisher
Apr 13, 2026

Aug Wrap: Is Fate Therapeutics Inc part of any ETFDay Trade & Daily Stock Trend Reports - baoquankhu1.vn

Apr 13, 2026
pulisher
Apr 13, 2026

FATE Q4 2025 Earnings: Fate Therapeutics Inc. tops EPS estimates, reports no revenueTrend Analysis - Cổng thông tin điện tử tỉnh Lào Cai

Apr 13, 2026
pulisher
Apr 10, 2026

Fate Therapeutics Inc stock (US3025491025): Is its iPSC platform strong enough to unlock biotech ups - AD HOC NEWS

Apr 10, 2026
pulisher
Apr 10, 2026

Fate Therapeutics Inc stock: Q2 2026 conferences signal active engagement - AD HOC NEWS

Apr 10, 2026
pulisher
Apr 10, 2026

FATE Q4 2025 Earnings: Fate Therapeutics Inc. posts narrow EPS beat, no revenue reportedElite Trading Signals - UBND thành phố Hải Phòng

Apr 10, 2026
pulisher
Apr 09, 2026

Fate Therapeutics to Participate in Upcoming Second Quarter 2026 Conferences - GlobeNewswire

Apr 09, 2026
pulisher
Apr 09, 2026

Fate Therapeutics plans appearances at 5 investor conferences by June - Stock Titan

Apr 09, 2026
pulisher
Apr 02, 2026

Fate Therapeutics reports new employee inducement award under Nasdaq listing rule 5635(c)(4) - marketscreener.com

Apr 02, 2026
pulisher
Apr 02, 2026

Fate Therapeutics Announces New Employee Inducement Award - National Today

Apr 02, 2026
pulisher
Apr 02, 2026

Fate Therapeutics Inc (F6T.DU) Stock Price, News, Quote & History - Yahoo! Finance Canada

Apr 02, 2026
pulisher
Mar 31, 2026

Street Watch: Is Fate Therapeutics Inc subject to activist investor interest2026 Rallies & Weekly Breakout Watchlists - baoquankhu1.vn

Mar 31, 2026
pulisher
Mar 31, 2026

FATE Should I Buy - Intellectia AI

Mar 31, 2026
pulisher
Mar 31, 2026

Fate Therapeutics Inc Stock: Pioneering iPSC Cell Therapies Amid Biotech Volatility - AD HOC NEWS

Mar 31, 2026
pulisher
Mar 31, 2026

Fate Therapeutics (NASDAQ:FATE) Share Price Passes Below 200-Day Moving AverageHere's What Happened - MarketBeat

Mar 31, 2026
pulisher
Mar 27, 2026

Scalable Biotech Manufacturing Unlocks a $14B Market - Benzinga

Mar 27, 2026
pulisher
Mar 27, 2026

Scalable Biotech Manufacturing Unlocks a $14B Market - Sahm

Mar 27, 2026
pulisher
Mar 26, 2026

Vanguard (FATE) reports 0 shares after internal realignment - Stock Titan

Mar 26, 2026

Fate Therapeutics Inc (FATE) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$28.32
price down icon 0.14%
$50.44
price up icon 0.48%
$95.50
price down icon 3.88%
$139.44
price down icon 0.41%
$147.21
price down icon 0.47%
ONC ONC
$297.49
price up icon 0.12%
大文字化:     |  ボリューム (24 時間):